Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial

Journal of the American Medical Association

Volumn 288, Issue 3, 2002, Pages 321-333

  Rossouw, Jacques E ^a   Anderson, Garnet L ^b   Prentice, Ross L ^b   LaCroix, Andrea Z ^b   Kooperberg, Charles ^b   Stefanick, Marcia L ^c   Jackson, Rebecca D ^d   Beresford, Shirley A A ^b   Howard, Barbara V ^e   Johnson, Karen C ^f   Kotchen, Jane Morley ^g   Ockene, Judith ^h  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c STANFORD UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e MEDSTAR RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HIP FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STROKE;

AGED; BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS DATA MONITORING COMMITTEES; COLORECTAL NEOPLASMS; CORONARY DISEASE; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FRACTURES, BONE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTMENOPAUSE; PROGESTERONE CONGENERS; PROPORTIONAL HAZARDS MODELS; PULMONARY EMBOLISM; RISK; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037125379     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.3.321     Document Type: Article

References (43)

1. Design of the Women's Health Initiative clinical trial and observational study
2. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
3. Hormone therapy to prevent disease and prolong life in postmenopausal women
4. Effects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: A review
5. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: Lack of an effect of added progesterone
6. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
7. Effect of estrone sulfate on postmenopausal bone loss
8. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
9. Reproductive factors, exogenous female hormones, and colorectal cancer by subsite
10. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
11. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study
12. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
13. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy
14. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
15. Effects of hormone replacement therapy on endometrial histofogy in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
16. Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health Study
17. Regression analysis and life tables
18. A multiple testing procedure for clinical trials
19. Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative
20. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
21. Estrogen replacement therapy: Determinants of persistence with treatment
22. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
23. Effects of estrogen replacement on the progression of coronary artery atherosclerosis
24. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina
25. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II)
26. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS)
27. A clinical trial of estrogen-replacement therapy after ischemic stroke
28. Estrogen in the prevention of atherosclerosis: A randomized, double-blind controlled trial
29. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial
30. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism a review
31. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/progestin Replacement Study
32. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
33. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II)
34. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
35. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
36. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
37. Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy
38. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
39. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis
40. Hormone replacement therapy and cardiovascular disease: The case for a randomized controlled trial
41. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials
42. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
43. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association